Blair C. Jackson - Feb 8, 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Signature
/s/ Shantale Greenson, attorney-in-fact for Blair C. Jackson
Stock symbol
ALKS
Transactions as of
Feb 8, 2024
Transactions value $
$162,062
Form type
4
Date filed
2/13/2024, 05:02 PM
Previous filing
Feb 24, 2023
Next filing
Feb 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Award +36.8K +32.28% 151K Feb 8, 2024 Direct F1, F2
transaction ALKS Ordinary Shares Tax liability -$295K -11K -7.29% $26.77 140K Feb 8, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Employee Stock Option (Right to Buy) Other $27.7K +599 +2% $46.24 30.6K Nov 17, 2023 Ordinary Shares 599 $46.24 Direct F3, F4
transaction ALKS Employee Stock Option (Right to Buy) Other $32.8K +469 +2% $69.83 24K Nov 17, 2023 Ordinary Shares 469 $69.83 Direct F3, F4
transaction ALKS Employee Stock Option (Right to Buy) Other $28.4K +899 +2% $31.64 45.9K Nov 17, 2023 Ordinary Shares 899 $31.64 Direct F3, F4
transaction ALKS Employee Stock Option (Right to Buy) Other $37.4K +699 +2% $53.50 35.7K Nov 17, 2023 Ordinary Shares 699 $53.50 Direct F3, F4
transaction ALKS Employee Stock Option (Right to Buy) Other $50K +759 +2% $65.94 38.8K Nov 17, 2023 Ordinary Shares 759 $65.94 Direct F3, F4
transaction ALKS Employee Stock Option (Right to Buy) Other $47.5K +1.49K +2% $31.93 76K Nov 17, 2023 Ordinary Shares 1.49K $31.93 Direct F3, F4
transaction ALKS Employee Stock Option (Right to Buy) Other $30.7K +1.53K +2% $20.03 78.3K Nov 17, 2023 Ordinary Shares 1.53K $20.03 Direct F3, F5
transaction ALKS Restricted Stock Unit Award Other +91 +1.98% 4.68K Nov 17, 2023 Ordinary Shares 91 Direct F3, F6, F7
transaction ALKS Employee Stock Option (Right to Buy) Other $60K +3.1K +2% $19.34 158K Nov 17, 2023 Ordinary Shares 3.1K $19.34 Direct F3, F8
transaction ALKS Restricted Stock Unit Award Other +380 +2% 19.4K Nov 17, 2023 Ordinary Shares 380 Direct F3, F6, F9
transaction ALKS Employee Stock Option (Right to Buy) Other $68.6K +2.79K +2% $24.59 142K Nov 17, 2023 Ordinary Shares 2.79K $24.59 Direct F3, F10
transaction ALKS Restricted Stock Unit Award Other +523 +2% 26.7K Nov 17, 2023 Ordinary Shares 523 Direct F3, F6, F11
transaction ALKS Employee Stock Option (Right to Buy) Other $73.5K +2.74K +2% $26.82 140K Nov 17, 2023 Ordinary Shares 2.74K $26.82 Direct F3, F12
transaction ALKS Restricted Stock Unit Award Other +685 +2% 35K Nov 17, 2023 Ordinary Shares 685 Direct F3, F6, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Late filing due to administrative error.
F2 These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs.
F3 Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
F4 These options are fully vested in accordance with their terms.
F5 Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.
F6 Each restricted stock unit represents a contingent right to receive one ordinary share.
F7 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.
F8 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.
F9 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.
F10 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.
F11 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.
F12 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.
F13 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

Remarks:

EXHIBIT LIST: Exhibit 24.1 - Power of Attorney